NiKogene is under clinical development by Kian Immune Cell and currently in Phase I for Pediatric Diffuse Intrinsic Pontine Glioma. According to GlobalData, Phase I drugs for Pediatric Diffuse Intrinsic Pontine Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the NiKogene LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
The therapeutic candidate is under development for the treatment of relapsed and refractory diffuse intrinsic pontine glioma (DIPG). It comprises of allogenic Natural Killer (NK) cells and is administered through intrathecal route.
Kian Immune Cell overview
Kian Immune Cell is a biotechnology company that generates immune cells from different type of stem cells and provides treatment to patients with oncology related diseases. The company is headquartered in Tehran, Iran.
For a complete picture of NiKogene’s drug-specific PTSR and LoA scores, buy the report here.